Story perspectives

Artisan Partners Demands Novartis Board Overhaul After 10% Drop

By Drooid · Sep 11, 2026, 4:22 AM UTC · How we work

Summary

Story summary

Artisan Partners, a major Novartis shareholder, demanded a board overhaul after shares fell over 10%.
The share drop followed a failed $12 billion Avidity acquisition drug study that erased nearly $30 billion in market value.
Investor David Samra urged the board to create an acquisition oversight committee and strengthen compensation metrics that exclude writedowns.
Samra did not blame CEO Vas Narasimhan, noting his leadership drove a 60% share-price rally since 2018.

1 of 1

Story summary

Artisan Partners, a major Novartis shareholder, demanded a board overhaul after shares fell over 10%.
The share drop followed a failed $12 billion Avidity acquisition drug study that erased nearly $30 billion in market value.
Investor David Samra urged the board to create an acquisition oversight committee and strengthen compensation metrics that exclude writedowns.
Samra did not blame CEO Vas Narasimhan, noting his leadership drove a 60% share-price rally since 2018.